2024年6月27日 · All formulations and fixed-dose combinations of dolutegravir (DTG) are U.S. Food and Drug Administration (FDA) approved for use in treatment-naive or treatment-experienced pediatric, adolescent, and adult patients naive to integrase strand transfer inhibitor (INSTI) drug class.

This document proposes the inclusion of dolutegravir (DTG) 10mg scored dispersible tablets for treatment of HIV-1 infection among pediatric patients (at least 4 weeks of age and weighing at least 3kg) living with HIV/AIDS on the core list of the Model List of Essential Medicines for Children (EMLc). DTG 50mg film

Three 10 mg dispersible tablets are equivalent to one 50 mg tablet. In children 20 kg and over, preferably use 50 mg tablet unless they cannot swallow tablets. Do not cut, crush or chew dispersible tablets. They can be swallowed or dispersed in a small amount of water.

Paediatric dolutegravir 10mg dispersible, scored tablets (pDTG) is a new generic formulation of DTG that allows antiretroviral treatment (ART) for children living with HIV (CLHIV) who are at least 4 weeks of age and weigh 3 to 20kg.

In November 2020, the United States Food and Drug Administration approved the first generic DTG 10-mg scored dispersible tablet. The proposed dosing for children is supported by data from the IMPAACT P1093 (Wiznia et al. and Ruel et al.) and

Building on the 2020 World AIDS Day announcement on pediatric dolutegravir (10mg) dispersible, scored tablets (pDTG), CHAI is pleased to share a set of resources to support national decision-making on and implementation for the optimal product, along with resources for the fixed-dose combination (FDC) of pediatric abacavir/lamivudine ...

2022年6月1日 · In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 mg scored, dispersible tablets, also known as paediatric DTG (pDTG). Rapid introduction and rollout of pDTG is a priority to implement the WHO guidelines and ensure that children living with HIV receive the best available ...

Antiretroviral, Integrase Strand Transfer Inhibitor (INSTI) HIV infection, in combination with other antiretrovirals. The 10 mg dispersible tablet for oral solution is intended for children from at least 4 weeks old and from 3 to 20 kg: Do not chew or crush the dispersible tablet.

Paediatric DTG 10 mg scored, dispersible tablets (pDTG) for CLHIV weighing a minimum of 3 kg and at least four weeks of age (pDTG) are currently administered along with optimised …

The dosing approach for DTG for children is simpler than it is for LPV/r: 10-milligram (mg), scored, dispersible pDTG tablets can be used from 4 weeks and 3 kg, and 50 mg, film-coated DTG tablets can be used from 20 kg onward.